Literature DB >> 35127085

Cervical dissecting extravasation of oxaliplatin: A case report.

Jorge Hernando1, Judit Riera-Arnau2, Maria Roca1, Alejandro Garcia1, Jaume Capdevila1.   

Abstract

Oxaliplatin is a chemotherapy drug considered to be an irritant and vesicant. Peripheral extravasation could happen following oxaliplatin chemotherapy administration, but mediastinal or cervical events are rare. The present study focused on the case of a 64-year-old female patient with KRAS-mutated colorectal adenocarcinoma. The patient was prescribed folinic acid, fluorouracil and oxaliplatin chemotherapy via a subcutaneous pump or port-a-cath device, which was inserted into the right subclavian vein. The patient reported a sudden throbbing pain in the chest wall and anterior cervical region. After performing a computed tomography scan, anterior cervical collection and jugular-subclavian venous confluence at the distal end was observed at the venous access site of the subcutaneous port-a-cath device, which extended cranially, dissected cervical planes and forming a hydro-aerial collection in the submaxillary region. Subsequently, the port-a-cath device was removed and a warm dry compress was applied. After 2 weeks, the patient had fully recovered without any sequelae at the cervical level. To the best of the authors' knowledge, this is the first case of cervical extravasation of oxaliplatin reported in the literature to date and will help to manage similar situations.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  extravasation; oxaliplatin

Year:  2022        PMID: 35127085      PMCID: PMC8771165          DOI: 10.3892/mco.2022.2493

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  21 in total

1.  Extravasations of oxaliplatin.

Authors:  Albrect Kretzschmar; Daniel Pink; Peter Thuss-Patience; Bernd Dörken; Peter Reichert; Robert Eckert
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

2.  Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre.

Authors:  F Narducci; M Jean-Laurent; L Boulanger; S El Bédoui; Y Mallet; J L Houpeau; A Hamdani; N Penel; C Fournier
Journal:  Eur J Surg Oncol       Date:  2011-08-09       Impact factor: 4.424

Review 3.  Overview, prevention and management of chemotherapy extravasation.

Authors:  Firas Y Kreidieh; Hiba A Moukadem; Nagi S El Saghir
Journal:  World J Clin Oncol       Date:  2016-02-10

Review 4.  Vesicant extravasation part II: Evidence-based management and continuing controversies.

Authors:  Rita Wickham; Constance Engelking; Carmel Sauerland; Dominick Corbi
Journal:  Oncol Nurs Forum       Date:  2006-11-27       Impact factor: 2.172

5.  Management of extravasation of oxaliplatin by mimicking its biotransformation.

Authors:  F Bahadori; M Demiray
Journal:  Clin Transl Oncol       Date:  2018-04-27       Impact factor: 3.405

Review 6.  [Update in the management of extravasations of cytocytostatic agent].

Authors:  D Conde-Estévez; J Mateu-de Antonio
Journal:  Farm Hosp       Date:  2011-07-27

7.  [Reversible tissue damage after paravasal infusion of oxaliplatin].

Authors:  Camilla Boesen; Svend Erik Nielsen
Journal:  Ugeskr Laeger       Date:  2015-01-19

Review 8.  Extravasation of oxaliplatin into the mediastinum: a case report and review of the literature.

Authors:  Roberto A Leon-Ferre; Taher B Abu Hejleh; Thorvardur R Halfdanarson
Journal:  Clin Adv Hematol Oncol       Date:  2012-08

9.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

Review 10.  Oxaliplatin: practical guidelines for administration.

Authors:  Joan Sorich; Beth Taubes; Allan Wagner; Howard Hochster
Journal:  Clin J Oncol Nurs       Date:  2004-06       Impact factor: 1.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.